Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study by Kearns, B.C. & Thomas, S.M.
Cost-effectiveness of superﬁcial femoral
artery endovascular interventions in the
UK and Germany: a modelling study
Benjamin C Kearns,1 Steven M Thomas2
To cite: Kearns BC,
Thomas SM. Cost-
effectiveness of superficial
femoral artery endovascular
interventions in the UK and
Germany: a modelling study.
BMJ Open 2017;7:e013460.
doi:10.1136/bmjopen-2016-
013460
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
013460).
Received 13 July 2016
Revised 15 September 2016
Accepted 3 October 2016
1The University of Sheffield,
Sheffield, UK
2Sheffield Teaching Hospitals,
Sheffield, UK
Correspondence to
Mr Benjamin C Kearns;
b.kearns@sheffield.ac.uk
ABSTRACT
Objectives: To assess the lifetime costs and cost-
effectiveness of 5 endovascular interventions to treat
superficial femoral arterial disease.
Design: A model-based health economic evaluation.
An existing decision analytical model was used, with
updated effectiveness data taken from the literature,
and updated costs based on purchasing prices.
Setting: UK and German healthcare perspectives were
considered.
Participants: Patients with intermittent claudication of
the femoropopliteal arteries eligible for endovascular
treatment.
Methods: UK and German healthcare perspectives
were considered, as were different strategies for re-
intervention.
Interventions: Percutaneous transluminal angioplasty
(PTA) with bail-out bare metal stenting (assumed to
represent the existing standard of care, and 4
alternatives: primary bare metal stents, drug-eluting
stents, drug-eluting balloons (DEBs) and biomimetic
stents).
Primary outcome measures: The incremental cost-
effectiveness ratio between 2 treatments, defined as the
incremental costs divided by the incremental quality-
adjusted life years (QALYs).
Results: Use of a biomimetic stent, BioMimics 3D,
was always estimated to dominate the other
interventions, having lower lifetime costs and greater
effectiveness, as measured by QALYs. Of the remaining
interventions, DEBs were always the most effective, and
PTA the least effective. There was uncertainty in the
cost-effectiveness results, with key drivers being the
costs and effectiveness of the biomimetic stent along
with the costs of DEBs.
Conclusions: All 4 of the alternatives to PTA were
more effective, with the biomimetic stent being the
most cost-effective. As there was uncertainty in the
results, and all of the interventions have different
mechanisms of action, all 4 may be considered to be
alternatives to PTA.
INTRODUCTION
Worldwide, more than 200 million people
are estimated to be living with peripheral
arterial disease (PAD).1 The presence of
PAD can have a signiﬁcant impact on an
individual’s quality of life and on the costs
incurred by the healthcare system, particu-
larly if multiple interventions are required.2
Historically, percutaneous transluminal
angioplasty (PTA) has been the main form
of treatment for PAD. However, recent
studies have demonstrated that alternative
interventions such as bare metal stents
(BMSs), drug-eluting stents (DESs) and
drug-eluting balloons (DEBs) have been
demonstrated to have favourable outcomes
on clinically important measures such as
long-term patency and the need for
re-intervention. In addition to clinical effect-
iveness, it is also important to consider cost-
effectiveness, in other words do these inter-
ventions represent value for money? This is
particularly important when considering
interventions for PAD, as these may be
Strengths and limitations of this study
▪ This study is the first cost-effectiveness analysis
to consider the four most promising alternatives
to standard endovascular care for superficial
femoral arterial disease: bare metal stents,
drug-eluting stents, drug-eluting balloons (DEBs)
and biomimetic stents.
▪ An existing decision analytical model, developed
for a previous National Institute for Health
Research funded economic evaluation, was
adapted to include a new intervention (biomim-
etic stents) and updated with more recent evi-
dence on costs and clinical effectiveness.
▪ We considered UK and German healthcare per-
spectives and were able to estimate the key
drivers of decision uncertainty and the value of
further research.
▪ The main limitations of the study are that there
are no head-to-head comparisons between bio-
mimetic stents and DEBs, the relatively small
sample size for biomimetic stents and that het-
erogeneity in purchasing strategies led to vari-
ation in the estimated costs of the interventions.
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associated with an increased initial cost, but could result
in savings over the longer term if the additional cost is
offset by savings as a result of reduced re-interventions
or lower complication rates. From a decision-making
viewpoint, cost-effectiveness is important because not all
effective interventions can be funded. Cost-effectiveness
results provide a framework to assist debates about
which interventions should and should not be funded.
A systematic review and economic evaluation of eight
enhancements to PTA was conducted in May 2011.3 It
identiﬁed that BMS, DES and DEB all resulted in an
improvement in health outcomes for patients when com-
pared to PTA alone. Of these interventions, the use of
DEB was estimated to result in the lowest lifetime costs
to the healthcare system and the greatest gains in health
outcomes for patients. However, notable limitations of
the economic evaluation included the lack of direct data
on re-intervention rates for many of the interventions
(instead changes in patency rates were assumed to
reﬂect changes in re-intervention rates), and the limited
follow-up data available, which was typically 12 months
(6 months for DEB). Since the publication of the ori-
ginal economic evaluation, more results have been pub-
lished which include evidence about the impact of
interventions on re-intervention rates and longer
follow-up data. In addition, evidence for a new class of
swirling ﬂow stents, known as biomimetic stents, has
begun to emerge.4 This stent is differentiated from trad-
itional BMSs as it imparts curvature to the artery, which
increases the arterial wall shear stress, reducing the
chance of restenosis.
The main aim of this study was to update the previous
economic evaluation to incorporate the latest evidence
relating to both the clinical effectiveness of treatments,
along with their costs. A secondary aim was to assess the
impact on cost-effectiveness of using different pricing
schemes and different methods to treat re-intervention.
METHODS
Previous economic evaluation
The previous economic evaluation, funded by the
National Institute for Health Research (NIHR), used a
decision analytical model (DAM) to synthesise data on
clinical effectiveness, costs to the healthcare system and
patient’s health-related quality of life. A comprehensive
overview of the methods used to construct the DAM,
and its input sources have previously been published.3 5
A brief overview of the key features of the model is pre-
sented here.
The patient population considered was those with
symptomatic infrainguinal PAD suitable for endovascular
treatment. It was assumed that PTA with bail-out BMS
represented existing standard care. The eight alternative
interventions considered were as follows: PTA with no
with no bail-out stenting, PTA with bail-out DES, DEB,
primary BMS, primary DES, endovascular brachytherapy,
stent grafts and cryoplasty. For drug-eluting
interventions, the drug considered was paclitaxel. It was
assumed that all re-interventions performed were either
bypass surgery (for acute failure; deﬁned as within
30 days) or PTA with bail-out BMS (for failure after
30 days). A systematic review and meta-analysis were
carried out to generate data on clinical effectiveness.6
Searches were conducted in May 2011. Six-month data
from the Zilver PTX study were published after this
review7 but used within the DAM. Patency rates for
standard care were taken from an existing
meta-analysis.8
Patients entered the DAM on receiving PTA or one of
the alternative interventions and had a probability of
perioperative mortality or acute failure. For patients who
remained alive and patent, long-term outcomes were
modelled. These included late failure (which may or may
not be accompanied by a return of symptoms), disease
progression following failure, the development of contra-
lateral symptoms or progressing to require amputation.
Late failure accompanied by the return of symptoms led
to re-intervention, which may also result in perioperative
mortality. Patients could also die at any point.
Lifetime outcomes were considered, with costs
reported in 2009–2010 British Pound Sterling and health
outcomes measured using quality-adjusted life years
(QALYs). QALYs are derived by applying a utility
(weight) to life years experienced, with a utility of one
indicating ‘perfect health’ and a utility of zero indicating
a state equivalent to death. Utility data for PAD were
taken from a previous economic evaluation.9 The per-
spective of the analysis was that of the UK National
Health Service (NHS), with cost data taken from national
guidance and national reference sources. For this study,
additional analyses were performed which considered
the perspective of the German healthcare system.
Clinical effectiveness evidence
Updated data on the clinical effectiveness of endovascu-
lar interventions were initially taken from the systematic
review and meta-analysis of Jens et al.10 The searches for
this review were conducted in November 2013. The
measure of clinical effectiveness used for this study was
the change in re-intervention rates, based on clinically
driven target lesion revascularisation (TLR). Differences
in TLR were reﬂected in the model by differences in the
rate of re-intervention. For each intervention, relative
risks (RRs) were calculated relative to PTA. For each
intervention, there were no differences in rates of mor-
tality or amputation.
In addition to the Jens et al meta-analysis, results for
biomimetic stents were taken from the Mimics study.4
The Mimics study was a multicentre randomised con-
trolled trial of patients receiving femoropopliteal inter-
vention. A total of 76 patients were enrolled, of whom
50 received the BioMimics 3D stent (Veryan Medical,
Horsham, UK), and 26 patients received a bare metal
(nitinol) stent. Follow-up was for 2 years. As this was the
only evidence about biomimetic stents that the authors
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were aware of, this study considered the cost-
effectiveness of the BioMimics 3D stent with the assump-
tion that this was representative of the class of biomim-
etic stents. For DESs, only one publication7 was included
in Jens et al.10 More recent data from this study (with
longer follow-up) have been published.11 Hence for
DESs this publication was used. Details on the derivation
of RRs from the Jens et al10 meta-analysis are provided in
the online supplementary material.
For this study, it was assumed that the effects of inter-
ventions only lasted for up to 1 year after the point at
which they were measured. As an example, if the effect
of an intervention on TLR was measured at 2 years, it
was assumed that this effect would persist for up to
3 years. This assumption was used to reﬂect the fact that
different studies reported effectiveness data for differing
lengths of follow-up. Where studies reported effective-
ness data at multiple time-points, the longest follow-up
time was used.
The use of DEB for re-interventions (instead of PTA)
was also considered.12 Hence, two analyses were con-
ducted from a UK perspective; one where PTA was used
to treat re-interventions, the other where DEB was used.
The analysis from a German perspective only considered
the use of DEB. It was assumed that the effectiveness of
DEB when used for re-interventions was the same as
when used for the initial intervention.
Of the eight interventions included in the previous
economic evaluation, the following were not considered
for this study: cryoplasty, stent graft, endovascular brachy-
therapy, PTA with no bail-out stenting and PTA with
bail-out DESs. This was because no data were available
relating to the effects of these interventions on TLR
rates.
Evidence on costs
Within the previous economic evaluation, cost data were
primarily drawn from a cost-effectiveness analysis per-
formed in support of guidance issued by the National
Institute for Health and Care Excellence (NICE).13
However, there was large uncertainty in these costs.
Hence for this study the costs of each intervention were
updated. The costs of PTA with bail-out BMSs were
taken from national NHS reference costs.14 It was
assumed that 32.4% of operations would require bail-out
stenting, based on values presented in the NICE cost-
effectiveness analysis.13 The costs of the remaining inter-
ventions were based on a mixture of company prices,
hospital prices and expert opinion. It was assumed that
PTA or DEB would cost the same regardless of whether
it was the primary intervention or a re-intervention. A
sensitivity analysis was conducted in which the cost of a
re-intervention was triple that of the initial procedure.
For the analysis from a German perspective, the cost
of PTA with bail-out bare metal stents was obtained by
converting the UK pound sterling price to Euros, assum-
ing a conversion rate of 1.2. Costs for the remaining
interventions were supplied by German purchasing
organisations. As there is no centrally agreed price for
each intervention, three different sets of estimates were
supplied. The cost-effectiveness of the interventions
under each set of costs was assessed.
The interventions considered for this economic evalu-
ation, along with the clinical and cost data used, are
summarised in table 1.
The costs of on-going PAD management were also
included in this study. It was assumed that patients with
intermittent claudication would require one outpatient
appointment every 3 months, while patients with critical
limb ischaemia would require a monthly outpatient
appointment and half-an-hour of a nurse’s time once
every 2 weeks. These assumptions were based on those
used in the previous economic evaluation by Sculpher
et al9 and were costed using national reference sources.15
Details of on-going resource use following an amputa-
tion were not available, so an annual cost of £23 502 was
used, taken from the NICE cost-effectiveness analysis.13
Assessment of cost-effectiveness
Interventions were compared in a fully incremental ana-
lysis for patients with intermittent claudication of the
femoropopliteal arteries. The analysis took either the
perspective of the UK NHS or the German healthcare
system, along with personal social services. Estimates of
costs to the healthcare system and beneﬁts to patients—
as measured by QALYs—were considered over a lifetime
horizon. Costs were reported in either 2013–2014 British
Pound Sterling or Euros. Costs and QALYs were dis-
counted at a rate of 3.5%/year, as recommended by
NICE.16 If an intervention generated more QALYs at less
cost than another intervention, the former dominated
the latter. Otherwise, the cost-effectiveness of an inter-
vention is determined by the willingness of a decision
maker to pay for an additional QALY. As this willingness
to pay is typically unknown, a range of different values
were considered. To generate results, 1000 probabilistic
sensitivity analysis (PSA) runs were implemented. These
willingness to pay values may be compared to incremen-
tal cost-effectiveness ratios (ICERs), deﬁned as the incre-
mental costs (when comparing two interventions)
divided by their incremental effects.
Value of information analyses were performed using
the Shefﬁeld Accelerated Value of Information web-
based application.17 18 The amount that should be spent
on conducting further research (known as the expected
value of perfect information) was estimated for
England19 and Germany,1 20 assuming that the preva-
lence of PAD was 360 599 and 1 930 000, respectively,
that 5.5% of patients with PAD would require an endo-
vascular procedure (based on the 20 000 procedures for
in England for 2010/20115) and that any intervention
would be adopted for 10 years with a willingness to pay
of £20 000. The partial expected value of perfect infor-
mation was also calculated to assess which parameters
contributed the most to decision uncertainty.
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RESULTS
Average lifetime cost-effectiveness results from the 1000
PSA runs are presented in tables 2 and 3, in ascending
order of costs. Table 2 presents results from a UK per-
spective under the two scenarios considered
(re-interventions with either PTA or DEB) while table 3
presents results from a German perspective using three
different sets of pricing estimates (all re-interventions
were with DEB). In addition to lifetime costs and
QALYs, table 2 also presents the lifetime costs of
re-operations and PAD management is also displayed.
These costs were similar when using a German perspec-
tive, so are not reported in table 3.
The results from all ﬁve analyses indicated that the
use of the biomimetic BioMimics 3D stent was associated
with the lowest lifetime costs and the highest number of
QALYs. In other words, the BioMimics 3D stent domi-
nated all of the other interventions. Of the remaining
interventions, the use of PTA with bail-out BMSs
(assumed current practice) was always associated with
the lowest lifetime costs, but also the lowest number of
QALYs. Of the remaining three interventions, the use of
DEBs was always estimated to be the most effective (in
terms of QALYs). For three of the ﬁve analyses
considered, the use of DEBs was estimated to dominate
the use of BMSs (being more effective and less costly).
DESs were estimated to be cheaper than DEBs in three
of the ﬁve analyses.
There were two main drivers for the cost savings
observed for the use of biomimetic stents: a reduction in
the number of repeat operations required, and a reduc-
tion in the average time spent with PAD (due to a loss of
patency and return of symptoms). These costs are dis-
played in table 2. The use of any of the interventions
was estimated to lead to a reduction in the average life-
time costs of re-operations and the average lifetime cost
of PAD management, relative to the use of PTA with
bail-out BMSs. The use of DEB for re-interventions
instead of PTA lowered the lifetime costs of PAD man-
agement, but increased the costs of re-operations.
Results from the sensitivity analysis (using a UK per-
spective), which assumed that repeat procedures cost an
average of £9744 (instead of £3248), indicated that the
use of either the biomimetic BioMimics 3D stent, DEBs
or DESs would result in lower lifetime costs than the use
of PTA with bail-out BMSs. Of these interventions, the
BioMimics 3Ds stent was still associated with the lowest
lifetime costs, followed by the use of DEBs.
Table 1 Clinical and cost data used
Cost estimates (2013/2014)
Intervention
RR; return of
symptoms*
Time period
(months) UK £ € (set 1) € (set 2) € (set 3)
PTA with bail-out bare metal stents 1 – £3248 €3898 €3898 €3898
Bare metal stents 0.7261 12 £3848 €4354 €4498 €4282
Drug-eluting stents 0.5216 60 £4208 €4678 €5053 €5038
Drug-eluting balloons 0.2739 18 £4604 €4848 €4888 €5360
Biomimetic (BioMimics 3D) stent 0.2711 24 £3968 €4618 €4618 €4618
All data are from Jens et al, with the exception of the biomimetic BioMimics 3D stent, which comes from the Mimics trial, and drug-eluting
stents, which comes from the 5-year Zilver PTX results.
*Defined as the need for clinically driven target lesion revascularisation.
PTA, percutaneous transluminal balloon angioplasty; RR, relative risk.
Table 2 Cost-effectiveness results; UK perspective
Intervention Costs (£) QALYs Costs of re-operations (£) Costs of PAD management (£)
All re-interventions PTA
Biomimetic (BioMimics 3D) stents £10 715 6.302 £2893 £524
PTA with bail-out bare metal stents £11 328 6.213 £3454 £1153
Drug-eluting stents £11 348 6.275 £3047 £713
Drug-eluting balloons £11 406 6.300 £2920 £540
Bare metal stents £11 498 6.242 £3273 £950
All re-interventions DEB
Biomimetic (BioMimics 3D) stents £10 838 6.330 £3261 £312
PTA with bail-out bare metal stents £11 019 6.286 £3787 £544
Bare metal stents £11 309 6.302 £3612 £457
Drug-eluting stents £11 325 6.318 £3399 £368
Drug-eluting balloons £11 515 6.329 £3287 £320
Values are lifetime averages per patient. Costs of PAD management exclude operation costs or costs relating to amputation.
DEB, drug-eluting balloon; PAD, peripheral arterial disease; PTA, percutaneous transluminal balloon angioplasty; QALYs, quality-adjusted life
years.
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The model results suggested that, while the use of the
biomimetic BioMimics 3D stent dominated each of the
other interventions, there was some uncertainty in these
results. This uncertainty is reﬂected in ﬁgure 1, which
displays the incremental costs and effects estimated from
each PSA run for each of the interventions compared to
of PTA with bail-out BMSs (under a UK perspective, with
PTA for re-interventions). The cloud of overlapping
points highlights the variation in cost-effectiveness
results. In particular, there was little estimated difference
in the effectiveness of the BioMimics 3D stent and
DEBs, with a difference in average lifetime QALYs of
0.002. Over the 1000 PSA runs, the use of the
BioMimics 3D stent was estimated to dominate use of
DEBs 39.2% of the time, but be dominated 16.9% of the
time.
The probability that each of the interventions was the
most cost-effective is displayed in a cost-effectiveness
acceptability curve in ﬁgure 2 (under a UK perspective,
with PTA for re-interventions). At a willingness to pay of
£0 (which implies that QALY gains are not considered),
the probability that the biomimetic BioMimics 3D stent
was cost-effective was 39.2%, while for DEBs and DESs
the probabilities were 15.7% and 16.0%, respectively. As
willingness to pay values increased, these values changed
to about 59% (BioMimics 3D stent), 31% (DEBs) and
8% (DESts).
The maximum amount that it is worth spending on
further research was estimated to be about £136 million
for England and about €1.1 billion for Germany. The
main sources of decision uncertainty were the costs of a
biomimetic stent and DEBs, which together contributed
to 68% of the decision uncertainty. In comparison, the
contribution to decision uncertainty due to the cost of
DESs was 11% while for BMSs it was 1%. Uncertainty in
the effectiveness of the biomimetic BioMimics 3D stent
contributed to 11% of the decision uncertainty; all
other inputs contributed <1% each.
DISCUSSION
The cost-effectiveness results suggested that the use of
the biomimetic BioMimics 3D stent dominated all of the
other interventions by being cheaper and more effective
over a patient’s lifetime. However, there was some uncer-
tainty in these results. All of the interventions consid-
ered were estimated to be more effective than the use of
PTA with bail-out BMSs, and relative to this their ICERs
were all well below the value of £20 000 stated as being a
threshold for cost-effectiveness in recent NICE
guidance.16
Within the UK, NICE make decisions about which
interventions should be made available via the NHS.
Table 3 Cost-effectiveness results; German perspective
Intervention Costs (€) set 1 Costs (€) set 2 Costs (€) set 3 QALYs
Biomimetic (BioMimics 3D) stents €11 576 €11 590 €11 764 6.330
PTA with bail-out bare metal stents €11 770 €11 786 €11 984 6.286
Drug-eluting balloons €11 848 €11 902 €12 549 6.329
Drug-eluting stents €11 886 €12 276 €12 439 6.318
Bare metal stents €11 911 €12 071 €12 044 6.302
Values are lifetime averages per patient. All re-interventions are with drug-eluting balloons.
PTA, percutaneous transluminal balloon angioplasty; QALYs, quality-adjusted life years.
Figure 1 Scatterplot of incremental costs and QALYs for
each intervention, relative to standard care. DEB, drug-eluting
balloon; DES, drug-eluting stent; QALYs, quality-adjusted life
years.
Figure 2 The probability that each of the interventions is
cost-effective, for different willingness to pay values. DEB,
drug-eluting balloon; DES, drug-eluting stent; QALYs,
quality-adjusted life years.
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Cost-effectiveness data have been identiﬁed as a key
component in NICE decision-making.21 The results pre-
sented here suggest that any of the alternatives to PTA
are potentially cost-effective options, with the use of bio-
mimetic stents predicted to lead to cost savings.
The use of the biomimetic stents has not been consid-
ered in previous economic evaluations, due to a lack of
evidence. Of the other interventions considered in the
NIHR-funded evaluation,5 results and their interpret-
ation were similar to this evaluation with the exception
of the lifetime costs for DEBs. In the previous evalu-
ation, these were estimated to be cheaper than the life-
time costs for PTA with bail-out BMSs, but for this
evaluation they were estimated to be £691 more expen-
sive. The key driver for this is the different method for
estimating the costs of an operation with a DEB. In the
previous evaluation, this was estimated to cost £232 more
than PTA with bail-out BMSs, with improved costing
information for this evaluation the cost was £1356 more.
Hence, the previously used value of £232 is likely to be
an underestimate. However, the use of DEBs was still esti-
mated to have a higher probability of being cost-effective
compared to PTA with bail-out BMSs for all willingness
to pay values. The economic evaluation performed to
support NICE guidance on PAD did not consider either
of the drug-eluting technologies due to a lack of evi-
dence over revascularisation rates.11 These data are now
available and have been incorporated into this model to
suggest that drug-eluting alternatives to PTA may be
cost-effective.
There are limitations with this work. First, there is a
lack of head-to-head comparisons between some of the
interventions; in particular, there is no direct compari-
son between the effectiveness of biomimetic stents and
DEBs. Second, differences in purchasing strategies result
in variation in the costs for the interventions considered.
The impact of this variation is highlighted by the value
of information results, which show that 68% of the deci-
sion uncertainty is driven by variation in the costs of bio-
mimetic stents and DEBs. Third, the cost-effectiveness
results reported for this study were from a model-based
economic evaluation. The use of a model was necessary
to synthesise data on effectiveness, costs and
health-related quality of life from multiple sources of evi-
dence. However, models are by deﬁnition a simpliﬁca-
tion of reality22 and require a number of assumptions
regarding the clinical pathway modelled and the deriv-
ation of lifetime costs. The assumptions used for this
study have been described in detail here and previ-
ously.3 5 Despite this, there is the potential that one or
more of these assumptions may be incorrect or that they
may not be applicable in different healthcare systems,
potentially limiting the generalisability of these results.
Finally, there is uncertainty in the results due to the rela-
tively small sample size of the MIMCS study when com-
pared to the other interventions. This uncertainty is
captured within the PSA as reﬂected, for example, by
the overlapping cloud of points for ﬁgure 2. Decisions
are usually made in a situation of uncertainty, and the
results from economic evaluations can assist in the
decision-making process. However, there may be reluc-
tance to choose the most cost-effective intervention (the
BioMimics 3D stent) due to the relatively small evidence
base. Hence, further research into this intervention may
have merit.
The maximum amount that should be spent on
further research was calculated using expected value of
information techniques. The estimated value for
Germany was about €1.1 billion, driven by the scale of
disease in this country.23 This value is an approximation
as it assumes that all of the decision uncertainty can be
reduced by collecting more data. However, it emphasises
the fact that future research into this disease is likely to
be a cost-effective use of resources in Germany.
Since the previous economic evaluation,5 there have
been two further studies reporting on the cost-
effectiveness of endovascular interventions for femoro-
popliteal arterial disease. One study24 considered the
24-month economic impact of DEB, DES and BMS rela-
tive to PTA. German and US healthcare perspectives
were considered. The authors found that, based on
pooled TLR data, all three alternatives were more effect-
ive than PTA, with both of the drug-eluting interventions
also having lower overall costs. An extension to the work
considered the same outcomes, but with a UK perspec-
tive,25 with device costs from market research data. The
authors found that while all of the alternatives to PTA
were again more clinically effective, they were also all
more expensive. Neither study considered lifetime out-
comes. In addition, a key assumption of both studies was
that TLR rates for PTA could be pooled across all
studies. The justiﬁcation for this assumption of a homo-
genous patient population is unclear, as there is substan-
tial variation in PTA TLR rates. For example, pooling
BMS studies give a 12-month TLR for PTA of 19.3%,
while pooling DEB studies give a 6-month TLR for PTA
of 31%10 (12-month data not available).
This study looked at four alternative interventions to
the use of PTA. Each of these interventions was asso-
ciated with an increased cost for the initial operation,
but also with a decrease in subsequent costs for
re-operations and the management of PAD. On purely
cost-effectiveness grounds, the use of the biomimetic
BioMimics 3D stent is recommended, as it was estimated
to be more effective and less costly than any of the other
interventions considered. However, each of the interven-
tions has a slightly different mechanism of action by
which it delays the need for revascularisation. Given the
importance of tailoring treatment to the individual, and
the uncertainty in the presented cost-effectiveness
results, all four interventions may be considered to be
potential alternatives to the use of PTA.
Impact on daily practice
In settings where there are restricted healthcare
budgets, it is becoming increasingly important to
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consider not just the effectiveness of interventions, but
also their cost-effectiveness. The use of alternative inter-
ventions to angioplasty, in particular biomimetic stents
or DEBs, is likely to be cost-effective. The use of a bio-
mimetic stent appears to be the most effective and also
the cheapest over a patient’s lifetime, although there is
uncertainty in this conclusion.
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